Research Roundup: Sept 30, 2025
- Lex Pelger
- Sep 30
- 3 min read
Best of cannabinoid science this week...
For chronic lower back pain, this 10-year study found “long-term cannabis therapy significantly reduced pain, disability, and opioid dependence… with sustained quality-of-life gains”
Long-Term Cannabis Therapy for Chronic Low Back Pain: A 10-Year Prospective Study
In adults with fetal alcohol spectrum disorder, a survey found that they use cannabis to manage sleeplessness & pain but reported adverse effects such as withdrawal, memory impairment & increased appetite
Patterns of Cannabis Use in Adults with Fetal Alcohol Spectrum Disorder (FASD)
In two children with Tourette's syndrome, cannabinoid-based medicines “resulted in continued benefit with significant improvement of tics and psychiatric comorbidities”
Long-Term Use of Cannabis-Based Medicines in Two Children with Tourette Syndrome: A Case Report
In two people with anxiety, the efficacy of CBD to lower anxiety levels was linked to an increased level of anandamide, suggesting it as an anxiety biomarker
Endocannabinoid signaling as a potential biomarker in anxiety spectrum disorders a case series
In adult mental health patients, a review of cannabinoids found suggested improvements in attention, cognitive inhibition, multitasking & normalization of brain activity during verbal memory tasks
The Effects of Medicinal Cannabis on Neurocognitive Functions of Adult Patients in Mental Health Care: A Systematic Review
For treatment-resistant epilepsy, this review recommended CBD for young people & adults
Cannabidiol: a new effective means for the treatment of patients with refractory epilepsy
And an analysis of its efficacy
Analysis of the efficacy and safety of cannabidiol in refractory epilepsy: A systematic review
For obesity, metabolic syndrome & binge eating, a review of the potential of CBD
Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
For intestinal fibrosis (scarring), a review of targeting the endocannabinoid system
The Endocannabinoid System as a Therapeutic Target in Intestinal Fibrosis
In a mouse model of opioids suppressing breathing, CBD was as effective as naloxone at preventing opioid-induced respiratory depression from fentanyl, with a synergy from combining them
Proof of Concept for High-Dose Cannabidiol Pretreatment to Antagonize Opioid Induced Persistent Apnea in Mice
In a rat model of heroin use disorder, CBD reduced cue-induced heroin-seeking behavior via changes to the nucleus accumbens (a reward center & regulator of feeding, stress & motivation)
Cannabidiol attenuates heroin seeking in male rats associated with normalization of discrete neurobiological signatures within the nucleus accumbens with subregional specificity
In rats with a fatty liver from a high-fat diet, a combination of exercise & CBD helped to regulate their lipid profiles & indicators of immune regulation & oxidative stress
The Effect of Aerobic Exercise and Cannabidiol Extract on SOCS3 Expression and SOD Activity in Rats with High-Fat Diet-Induced Fatty Liver
In an aged rat model of obesity, CBD reduced the inflammatory effects of obesity, their anxiety-like behaviors & their neuroinflammation in the prefrontal cortex
Cannabidiol attenuates diet-induced metabolic endotoxemia, neuroinflammation, and anxiety-like behaviors in male aged rats
In a mouse model of obesity, the terpene beta-caryophyllene modulated key receptors of appetite regulation & insulin sensitivity (including FFAR3, LEPR, & GHSR) & its actions on the CB2 receptor suggested additional benefits for energy balance & appetite reduction
Effect of β-Caryophyllene on PPAR-γ NF-κB and CNR2: Implications for Gut–Brain Axis Communication in a Murine Model of Diet-Induced Obesity
In a mouse model of neuropathic pain, CBD reduced the pain at least partially via the opioid receptors
Cannabidiol engages the peripheral endogenous opioid system to produce analgesia in neuropathic mice
In a mouse model of metabolic dysfunction-associated steatohepatitis (MASH, formerly known as fatty liver disease), a nano-oleoylethanolamide (the endocannabinoid of satiation) reached the liver & “demonstrated remarkable efficacy in suppressing the rapid progression of MASH symptoms”
Enzyme-responsive oleoylethanolamide-releasing nanomedicine for sustained liver delivery and therapeutic improvement in early-stage metabolic dysfunction-accosicated steatohepatitis (MASH)
Comments